CMR Surgical, a global surgical robotics company, has successfully secured over €185 million in a recent financing round to support its growth plans.
The fundraising was backed by existing major investors and includes a new debt investment from Trinity Capital, with Armentum Partners as the financial advisor.
The funds will be used to expand commercial reach of the Versius Surgical Robotic System globally, especially targeting the U.S. market, and fuel innovation.
CMR aims to provide robotic assisted surgery to patients worldwide and enhance surgical robotics technology with the launch of Versius Plus.
Versius is a next-generation surgical robot designed for minimal access surgery, offering versatility in operating room set-ups and enhancing surgeon control and comfort.
CMR emphasizes that Versius is more than just a robot, capturing data for continual learning and improvement of surgical care through its digital ecosystem.
The successful funding round demonstrates confidence in CMR and the potential of surgical robotics, contributing to the UK's innovative life science ecosystem.
Versius has been utilized in over 30,000 surgical cases globally across various specialties, making it the second most used soft tissue surgical robot worldwide.
CMR is conducting clinical trials to further expand Versius' applications, including a paediatrics study and a transoral robotic surgery trial.
Trinity Capital and investors express confidence in CMR's leadership and vision, anticipating further advancements in minimally invasive surgery on a global scale.